Dr. Ashley Ross, MD
Claim this profileMary Crowley Cancer Research Centers
Studies Prostate Cancer
Studies Prostate Adenocarcinoma
4 reported clinical trials
7 drugs studied
Area of expertise
1Prostate Cancer
PSA positive
PSA negative
Stage IV
2Prostate Adenocarcinoma
PSA positive
PSA negative
Affiliated Hospitals
Clinical Trials Ashley Ross, MD is currently running
Neoadjuvant Enoblituzumab
for Prostate Cancer
This study evaluates the efficacy, anti-tumor effect, and immunogenicity of neoadjuvant enoblituzumab given before radical prostatectomy. Patients will be randomized to enoblituzumab for a total of 12 weeks beginning 84 days before radical prostatectomy or standard of care arms.
Recruiting1 award Phase 218 criteria
PET-MRI Imaging
for Prostate Cancer
This clinical trial evaluates whether positron emission tomography-magnetic resonance imaging (PET-MRI) using the radioactive drug radiohybrid prostate-specific membrane antigen (rhPSMA)-7.3 may help in detecting higher grade or stage disease in men with low and favorable intermediate risk prostate cancer who are candidates for active surveillance. A PET scan is a test that uses a radioactive drug and a computer to create images of how organs and tissues in the body are functioning. The radioactive drug used in this study, rhPSMA-7.3, attaches to the abnormal cells in the body at a different rate than normal cells which allows the scanner to create a detailed picture of how the body is working. An MRI scan uses strong magnets and computers to create detailed images of the soft tissue in your body. A multiparametric (mp)MRI is a type of MRI scan that creates a more detailed picture of the prostate gland. Using rhPSMA-73 with PET-MRI and mpMRI may be more effective in detecting higher grade or stage disease in men with low and favorable intermediate risk prostate cancer.
Recruiting1 award Phase < 1
More about Ashley Ross, MD
Clinical Trial Related6 years of experience running clinical trials · Led 4 trials as a Principal Investigator · 2 Active Clinical TrialsTreatments Ashley Ross, MD has experience with
- RhPSMA-7.3 PET-MRI Imaging
- Afuresertib
- LAE001
- Prednisone
- Proxalutamide (GT0918)
- Enoblituzumab
Breakdown of trials Ashley Ross, MD has run
Prostate Cancer
Prostate Adenocarcinoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Ashley Ross, MD specialize in?
Ashley Ross, MD focuses on Prostate Cancer and Prostate Adenocarcinoma. In particular, much of their work with Prostate Cancer has involved PSA positive patients, or patients who are PSA negative.
Is Ashley Ross, MD currently recruiting for clinical trials?
Yes, Ashley Ross, MD is currently recruiting for 2 clinical trials in Dallas Texas. If you're interested in participating, you should apply.
Are there any treatments that Ashley Ross, MD has studied deeply?
Yes, Ashley Ross, MD has studied treatments such as rhPSMA-7.3 PET-MRI Imaging, Afuresertib, LAE001.
What is the best way to schedule an appointment with Ashley Ross, MD?
Apply for one of the trials that Ashley Ross, MD is conducting.
What is the office address of Ashley Ross, MD?
The office of Ashley Ross, MD is located at: Mary Crowley Cancer Research Centers, Dallas, Texas 75251 United States. This is the address for their practice at the Mary Crowley Cancer Research Centers.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.